SapVax, LLC
The startup develops cancer immunotherapy adjuvants utilizing a peptide platform that targets specific antigens found in various cancers and virus proteins linked to nasopharyngeal cancer, lymphoma, and gastric cancer. This technology enhances the efficacy of vaccines, enabling oncologists to achieve better treatment outcomes for patients.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$3.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops cancer immunotherapy adjuvants utilizing a peptide platform that targets specific antigens found in various cancers and virus proteins linked to nasopharyngeal cancer, lymphoma, and gastric cancer. This technology enhances the efficacy of vaccines, enabling oncologists to achieve better treatment outcomes for patients.